| Literature DB >> 32512197 |
Lionel Velly1, Etienne Gayat2, Hervé Quintard3, Emmanuel Weiss4, Audrey De Jong5, Philippe Cuvillon6, Gérard Audibert7, Julien Amour8, Marc Beaussier9, Matthieu Biais10, Sébastien Bloc11, Marie Pierre Bonnet12, Pierre Bouzat13, Gilles Brezac14, Claire Dahyot-Fizelier15, Souhayl Dahmani16, Mathilde de Queiroz17, Sophie Di Maria18, Claude Ecoffey19, Emmanuel Futier20, Thomas Geeraerts21, Haithem Jaber22, Laurent Heyer23, Rim Hoteit24, Olivier Joannes-Boyau25, Delphine Kern26, Olivier Langeron27, Sigismond Lasocki28, Yoan Launey29, Frederic le Saché30, Anne Claire Lukaszewicz31, Axel Maurice-Szamburski32, Nicolas Mayeur33, Fabrice Michel34, Vincent Minville35, Sébastien Mirek36, Philippe Montravers37, Estelle Morau38, Laurent Muller39, Jane Muret40, Karine Nouette-Gaulain41, Jean Christophe Orban42, Gilles Orliaguet43, Pierre François Perrigault44, Florence Plantet45, Julien Pottecher46, Christophe Quesnel47, Vanessa Reubrecht18, Bertrand Rozec48, Benoit Tavernier49, Benoit Veber50, Francis Veyckmans51, Hélène Charbonneau33, Isabelle Constant52, Denis Frasca53, Marc-Olivier Fischer54, Catherine Huraux55, Alice Blet56, Marc Garnier57.
Abstract
OBJECTIVES: The world is currently facing an unprecedented healthcare crisis caused by the COVID-19 pandemic. The objective of these guidelines is to produce a framework to facilitate the partial and gradual resumption of intervention activity in the context of the COVID-19 pandemic.Entities:
Keywords: Airway management; COVID-19; Infection prevention and control; Personal protective equipment; SARS-CoV-2; Viruses
Mesh:
Year: 2020 PMID: 32512197 PMCID: PMC7274119 DOI: 10.1016/j.accpm.2020.05.012
Source DB: PubMed Journal: Anaesth Crit Care Pain Med ISSN: 2352-5568 Impact factor: 4.132
Personal protective equipment (PPE) depending on the place and the procedures that are performed in adult patients and healthcare professionals.
| Safety measures | Preanaesthetic assessment | Operating rooms, interventional platforms? | Recovery room | Critical care units or intermediate care units |
|---|---|---|---|---|
| Healthcare professionals | Caring for a known or suspected case of COVID-19 | |||
| Hand disinfection with a hydro-alcoholic based hand gel, wearing a surgical mask type II/IIR and safety goggles | N95 or FFP2 respirator, head cap, fluid resistant long-sleeved gown (or failing that, a surgical gown) + plastic apron, disposable gloves and a face shield (or failing that, safety goggles) | N95 or FFP2 respirator, head cap, fluid resistant long-sleeved gown (or failing that, a surgical gown) + plastic apron, disposable gloves and a face shield (or failing that safety goggles) | ||
| Caring for non-COVID patients | ||||
| Hand disinfection with a hydro-alcoholic based hand gel, surgical mask type II/IIR | Intubation and extubation: N95 or FFP2 respirator, head cap, plastic apron, disposable gloves and a face shield (or failing that, safety goggles) | Extubation (not recommended in recovery rooms): N95 or FFP2 respirator, head cap, plastic apron, disposable gloves and a face shield (or failing that, safety goggles) | Surgical mask type II/IIR | |
| Patients | Known or suspected case of COVID-19 | |||
| Hand disinfection with a hydro-alcoholic based hand gel, a surgical mask type II/IIR | Patients must wear a surgical mask type II/IIR when leaving their unit and heading for the OR | Surgical mask type II/IIR | ||
| Non-COVID patients | ||||
| Hand disinfection with a hydro-alcoholic based hand gel, surgical mask type II/IIR | Patients should wear a surgical mask type II/IIR when leaving their unit and heading for the OR | After extubation, patients should wear a surgical mask type II/IIR | No mask, except if the patient is presenting with COVID-19 symptoms → surgical mask type II/IIR | |
Criteria for assessing the benefit/risk ratio of surgical intervention in a patient during the COVID-19 pandemic.
| Factors |
|---|
| Related to the patient |
| ASA class |
| Obesity (IMC ≥ 30 kg/m2) |
| Age (> 65 years, < 1 year) |
| Underlying respiratory (asthma, COPD, cystic fibrosis) or cardiovascular (hypertension, coronary artery disease and chronic heart failure) pathology |
| Obstructive sleep apnea syndrome |
| Diabetes |
| Immunosuppression |
| Related to the disease |
| Possible therapeutic alternatives |
| Loss of chance in the absence of intervention |
| Related to the procedure |
| Operating time |
| Duration of stay |
| Need for critical care |
| Transfusion needs |
| Number of staff needed in the operating room |
| Anaesthesia modality |
| Surgery site |
Fig. 1Scheduled surgery.
Fig. 2Emergency surgery.
Possible drug interactions between drugs used in perioperative care and anti-SARS-CoV-2, based on https://www.covid19-druginteractions.org/.
| Lopinavir/ritonavir | Remdesivir | Hydroxychloroquine | Tocilizumab | Interferon beta | |
|---|---|---|---|---|---|
| Bupivacaine | ↑ | ←→ | ←→ | ↓ | ←→ |
| Lidocaine | ↑ | ←→ | ←→ | ←→ | ←→ |
| Propofol | ↓♥ | ←→ | ←→♥ | ←→ | ←→ |
| Kétamine | ↑ | ←→ | ←→ | ↓ | ←→ |
| Thiopental | ↑ | ←→ | ←→ | ←→ | ←→ |
| Midazolam IV | ↑ | ←→ | ←→ | ←→ | ←→ |
| Midazolam per os | ↑ | ←→ | ←→ | ←→ | ←→ |
| Sevoflurane | ←→♥ | · | ←→♥ | · | · |
| Desflurane | ←→ | ←→ | ←→ | ←→ | ←→ |
| Clonidine | ←→ | ←→ | ←→ | ←→ | ←→ |
| Dexmedetomidine | ↓♥ | ←→ | ←→♥ | ←→ | ←→ |
| Suxamethonium | ←→ | ←→ | ←→ | ←→ | ←→ |
| Vecuronium | ←→ | ←→ | ←→ | ←→ | ←→ |
| Atracurium | ←→ | ←→ | ←→ | ←→ | ←→ |
| Cisatracurium | ←→ | ←→ | ←→ | ←→ | ←→ |
| Rocuronium | ↑ | ←→ | ←→ | ←→ | ←→ |
| Fentanyl | ↑ | ←→ | ←→ | ↓ | ←→ |
| Remifentanil | ←→ | ←→ | ←→ | ←→ | ←→ |
| Sufentanil | ↑ | ←→ | ←→ | ↓ | ←→ |
| Morphine | ↓ | ←→ | ←→ | ←→ | ←→ |
| Hydrocodone | ↓ ↑♥ | ←→ | ↑♥ | ←→ | ←→ |
| Codeine | ↑ | ←→ | ←→ | ←→ | ←→ |
| Dextropropoxyphene | ↑ | ←→ | ←→ | ↓ | ←→ |
| Oxycodone | ↑ (160%) | ←→ | ←→ | ↓ | ←→ |
| Tramadol | ↑♥ | ←→ | ←→♥ | ←→ | ←→ |
| Paracetamol | ←→ | ←→ | ←→ | ←→ | ←→ |
| Diclofenac | ←→ | ←→ | ←→ | ←→ | ←→ |
| Ibuprofene | ←→ | ←→ | ←→ | ←→ | ←→ |
| Enoxaparine | ←→ | ←→ | ←→ | ←→ | ←→ |
| Dabigatran | ↓ or ↑ | ←→ | ↑ | ←→ | ←→ |
| Rivaroxaban | ↑ | ←→ | ↑ | ↓ | ←→ |
| Apixaban | ↑ | ←→ | ↑ | ↓ | ←→ |
| Fondaparinux | ←→ | ←→ | ←→ | ←→ | ←→ |
| Heparine | ←→ | ←→ | ←→ | ←→ | ←→ |
| Haloperidol | ↑♥ | ←→ | ←→♥ | ←→ | ←→ |
| Alprazolam | ↑ | ←→ | ←→ | ←→ | ←→ |
| Bromazepam | ↑ | ←→ | ←→ | ←→ | ←→ |
| Diazepam | ↑ | ←→ | ←→ | ←→ | ←→ |
| Oxazepam | ←→ | ←→ | ←→ | ←→ | ←→ |
| Zolpidem | ↑ | ←→ | ←→ | ←→ | ←→ |
| Hydroxyzine | ↑ | ←→ | ←→ | ←→ | ←→ |
| Droperidol | ↑♥ | ←→ | ←→♥ | ←→ | ←→ |
| Odansetron | ↑♥ | ←→ | ←→♥ | ←→ | ←→ |
| Dexamethasone | ↑ + | ←→ | ←→ | ←→ | ←→ |
♥: risk of cardiac toxicity; ↑: increased drug exposure; ↓: decreased drug exposure; : decrease in antiviral exposure; ←→: no effect.
Significant interaction, association not recommended.
Possible interaction, dose adjustment or monitoring recommended.
Low intensity interaction, no adjustment required.
No significant interaction.
Fig. 3Suggested patient pathway based on COVID status.
Fig. 4Interactions of the Multidisciplinary Regulatory Committee.